Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950660 · ClinicalTrials.gov registry record · Phase 4
Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion
A Phase 4 study, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT04950660: Completed Phase 4 study, sponsored by Children's Mercy Hospital Kansas City.
NCT04950660 is a Phase 4 study that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 61 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04950660, a Phase 4 study, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
Prospective, randomized control trial To determine if oral caffeine decreases the frequency of opioid demand in children with adolescent idiopathic scoliosis after their spinal fusion surgery To compare pain scale ratings, number of requests for diazepam, average heart rate, average blood pressure, sex, age, ethnicity, post-op day of discharge, operative time, estimated intraoperative blood loss, remittance post-surgery, length of hospital stay, and segments fused during spinal fusion surgery.
Primary Outcome
Total Post Operative Oral Morphine milligram equivalents (MME)/kilogram (Kg) for Hospital Stay
Interventions
- DRUG Placebo
- DRUG Caffeine Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 4 |
What the finished NCT04950660 record still lists
NCT04950660 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04950660 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04950660 about?
NCT04950660 is a clinical study titled "Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion". Prospective, randomized control trial To determine if oral caffeine decreases the frequency of opioid demand in children with adolescent idiopathic scoliosis after their spinal fusion surgery To compare pain scale ratings, number of requests for diazepam, average heart rate, average blood pressure, ...
What is the current status of trial NCT04950660?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2019-12-11. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT04950660?
The interventions under investigation include: Placebo (DRUG), Caffeine Tablet (DRUG).
Who is sponsoring clinical trial NCT04950660?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04950660's enrollment target sits among peer trials
61 1119th of 2000 higher than 876 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI